Performance was strong in the U.S. and Europe, with mixed results in Asia. In China, the environment remains largely consistent, with recent quarters reflecting relatively low tender activity across the category, domestic competition, and policy-driven pricing pressure. Given our belief in the long-term opportunity, we continue to make investments to improve procedure growth, establish favorable patient charge codes, and support other market access activities.